18 June 2021 - Onureg is the first and only once daily, frontline oral maintenance therapy in the European Union for patients with a broad range of acute myeloid leukaemia sub-types.

Bristol Myers Squibb today announced that the European Commission has granted full marketing authorisation for Onureg (azacitidine tablets) as a maintenance therapy in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation.

Read BMS press release